A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer
Ashish M Kamat* and Colin PN Dinney
Correspondence *Department of Urology, Unit 1373, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
Email akamat@mdanderson.org
This article has no abstract so we have provided the first paragraph of the full text.
To date, intravesical BCG immunotherapy is the most effective therapy for superficial bladder cancer, with a positive effect on tumor recurrence and disease progression.1 Intravesical chemotherapy, on the other hand, has consistently been shown to reduce short-term recurrence rates, but has no impact on disease progression. In an attempt to exploit the differing mechanisms of action, combination therapy with intravesical BCG and chemotherapy has been attempted,2, 3 but with disappointing results—until now.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.